Our reviews

Our Reviews

Full list:

By subtopic:

Pharmacological interventions for Multiple Sclerosis (37)
Aminopyridine (1)
Aminopyridines for symptomatic treatment in multiple sclerosis
Biologics (7)
Alemtuzumab (2)
Alemtuzumab for multiple sclerosis
alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis
Daclizumab (1)
Daclizumab for relapsing remitting multiple sclerosis
Natalizumab (1)
Natalizumab for relapsing remitting multiple sclerosis
Ocrelizumab (1)
Ocrelizumab for multiple sclerosis (protocol stage)
Rituximab (2)
Rituximab for people with multiple sclerosis (protocol stage)
Rituximab for relapsing-remitting multiple sclerosis
T-cell vaccination (0)
Immunosuppressants (9)
Azathioprine (2)
Azathioprine for people with multiple sclerosis (protocol stage)
Azathioprine for multiple sclerosis
Bone Marrow Transplantation (0)
Cladribine (1)
Cladribine for people with multiple sclerosis (protocol stage)
Cyclosphosphamide (1)
Cyclophosphamide for multiple sclerosis
Cyclosporin A (0)
Fingolimod (1)
Fingolimod for relapsing-remitting multiple sclerosis
Methotrexate (1)
Methotrexate for multiple sclerosis
Mitoxantrone (1)
Mitoxantrone for multiple sclerosis
Teriflunomide (1)
Teriflunomide for multiple sclerosis
Mycophenolate Mofetil (1)
Mycophenolate mofetil for relapsing-remitting multiple sclerosis
Total Lymphoid Irradiation (0)
Immunomodulators (10)
Dimethyl fumarate (1)
Dimethyl fumarate for multiple sclerosis
Glatiramer acetate (1)
Glatiramer acetate for multiple sclerosis
Immunoglobulins (1)
Intravenous immunoglobulins for multiple sclerosis
Interferons: recombinant alpha-2a, recombinant beta-1a and beta-1b (5)
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis
Interferon beta for secondary progressive multiple sclerosis
Interferon in relapsing-remitting multiple sclerosis
Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis
Interferon Beta for Primary Progressive Multiple Sclerosis
Interleukine(s) (0)
Laquinimod (0)
Ozanimod (1)
Ozanimod for relapsing-remitting multiple sclerosis (protocol stage)
Plasma Exchange (0)
Siponimod (1)
Siponimod for multiple sclerosis (protocol stage)
Immunotherapies (4)
Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis (protocol stage)
Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis
Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis
Statins (1)
Statins for multiple sclerosis
Steroids (3)
Oral versus intravenous steroids for treatment of relapses in multiple sclerosis
Corticosteroids for the long-term treatment in multiple sclerosis
Corticosteroids or ACTH for acute exacerbations in multiple sclerosis
Vitamins (1)
Vitamin D for the management of multiple sclerosis
Others (1)
Sodium channel blockers for neuroprotection in multiple sclerosis
Non pharmacological interventions for Multiple Sclerosis (19)
Alternative therapies (i.e. acupuncture) (0)
Diet (1)
Dietary interventions for multiple sclerosis-related outcomes
Hyperbaric Oxygen (1)
Hyperbaric oxygen therapy for multiple sclerosis
Psychological therapy (2)
Psychological interventions for enhancing adherence to disease-modifying therapies (DMTs) in multiple sclerosis (protocol stage)
Psychological interventions for multiple sclerosis
Rehabilitation (13)
Conservative interventions for urinary or faecal incontinence, or both, in adults with multiple sclerosis (protocol stage)
Exercise therapy for fatigue in multiple sclerosis
Interventions for preventing falls in people with multiple sclerosis
Memory rehabilitation for people with multiple sclerosis
Multidisciplinary rehabilitation for adults with multiple sclerosis
Occupational therapy for multiple sclerosis
Neuropsychological rehabilitation for multiple sclerosis
Rehabilitation for people with multiple sclerosis: an overview of Cochrane Reviews
Respiratory muscle training for multiple sclerosis
Telerehabilitation for persons with multiple sclerosis
Exercise therapy for multiple sclerosis
Virtual reality for multiple sclerosis rehabilitation (protocol stage)
Effectiveness of vocational rehabilitation intervention on the return to work and employment of persons with multiple sclerosis
Surgery (2)
Percutaneous transluminal angioplasty for treatment of chronic cerebrospinal venous insufficiency (CCSVI) in people with multiple sclerosis
Ventriculo-peritoneal shunting devices for hydrocephalus
Others (0)
Non pharmacological interventions for symptons of Multiple Sclerosis (2)
Chronic pain (1)
Non-pharmacological interventions for chronic pain in multiple sclerosis
Multiple symptoms (1)
Transcranial direct current stimulation (tDCS) for improving fatigue, motor function, and pain in people with multiple sclerosis (protocol stage)
Spasticity (0)
Palliative Care for Multiple Sclerosis (1)
Palliative care interventions for people with multiple sclerosis
Prognosis (1)
Overall prognosis (0)
Predictive/Treatment selection factors (0)
Prognostic factors (0)
Prognostic models (1)
Prognostic models for predicting clinical disease progression, worsening and activity in people with multiple sclerosis (protocol stage)
Symptomatic treatments (Pharmacological Interventions) for Multiple Sclerosis (11)
Cognitive problems (1)
Pharmacological treatment for memory disorder in multiple sclerosis
Seizures (1)
Treatment of seizures in multiple sclerosis
Spasticity (1)
Baclofen (0)
Benzodiazepine (0)
Botulinum toxin (0)
Dantrolene (0)
Tizanidine (0)
Anti-spastic drugs/interventions (1)
Anti-spasticity agents for multiple sclerosis
Treatment for movement disorder (1)
Botulinum Toxin (0)
Clonazepam (0)
Dalfampridine (0)
Gabapentin (0)
Pregabalin (0)
Primidone (0)
Treatments/interventions for ataxia/tremor (1)
Treatment for ataxia in multiple sclerosis
Psychological-Emotional problems (1)
Benzodiazepine (0)
Monoamine Oxidase Inhibitor (MAOI) (0)
Other pharmacological interventions (1)
Pharmacologic treatment of depression in multiple sclerosis
Selective Serotonin Reuptake Inhibitor (SSRI) (0)
Tricyclic antidepressant (0)
Urinary problems (0)
Imipramine (0)
Propantheline (0)
Spastic bladder (0)
Anticholinergic agents (0)
Baclofen (0)
Diazepam (0)
Urinary frequency and urgency (0)
Desmopressin, Vasopressin (0)
Oxybutynin (0)
Urinary hesitancy (0)
Phenoxybenzamine (0)
Terazosin (0)
Urinary tract infections (UTI) (0)
Urinary urgency and incontinence (0)
Bethane (0)
Carbamazepine (0)
Imiprenine (0)
Tolterodine (0)
Bowel problems (0)
Dizziness and Vertigo (0)
Dimenhydrinate (0)
Diphenhydramine (0)
Meclizine (0)
Prochlorperazine (0)
Scopolamine (0)
Fatigue (2)
Amantadine (1)
Amantadine for fatigue in multiple sclerosis
Carnitine (1)
Carnitine for fatigue in multiple sclerosis
Fluoxetine (0)
Modafinil (0)
Pemoline (0)
Pain and Dysaesthesia (1)
Amitriptyline (0)
Carbamazepine (0)
Desipramine (0)
Doxepin (0)
Gabapentin (0)
Imipramine (0)
Multiple treatments (1)
Pharmacological treatment for chronic central neuropathic pain in people with multiple sclerosis (protocol stage)
Phentoin (0)
Protriptyline (0)
Topiramate (0)
Ziconotide (0)
Zonisamide (0)
Sexual dysfunctions (2)
Prostaglandins (1)
Prostaglandin E1 for treatment of erectile dysfunction
Sildenafil (1)
Sildenafil citrate for erectile dysfunction in patients with multiple sclerosis
Symptoms (1)
Cannabis and cannabinoids for people with multiple sclerosis (protocol stage)
Health services for Multiple Sclerosis (2)
Multiple intervention modalities (inpatient, outpatient, day-hospital, home treatment) (0)
Delivery of care (0)
Information provision to patients and caregivers (1)
Information provision for people with multiple sclerosis
Patient education programmes (1)
Patient education for fatigue in people with multiple sclerosis (protocol stage)
Physical and transportation barriers (0)
Preventive health care (services) (0)
Falls (0)
Rehabilitation services (0)
Outcome Measures (0)
Clinical outcomes and natural history (0)
Immunological-devised outcomes (0)
Resonance Imaging-devised outcomes (0)
Vaccinations (0)
Rare Diseases of the Central Nervous System (3)
Inflammatory disorders (1)
Encephalomyelitis (1)
Disseminated encephalomyelitis (0)
Myelitis (0)
Encephalitis (1)
Intravenous immunoglobulin for the treatment of childhood encephalitis
Neuromyelitis optica (0)
Neurosarcoidosis (0)
Hereditary disorders (0)
Choreoacanthocytosis (0)
Familial spastic paraplegia (0)
Storage disease (0)
Neuronal Ceroid-Lipofuscinoses (0)
Leukodystrophies (0)
Infectious disorders (1)
Prevention of CSF-shunt infection (1)
Route of antibiotic prophylaxis for prevention of cerebrospinal fluid-shunt infection
Progressive Multifocal Leukoencephalopathy (0)
Whipple disease (0)
Mitochondrial disorders (0)
Leber disease (0)
Melas syndrome (0)
Other disorders (0)
Vasculitis disorders (1)
Neuro-Behçet disease (1)
Biologics, colchicine, corticosteroids, immunosuppressants and interferon-alpha for Neuro-Behçet's Syndrome
Churg-Strauss syndrome (0)
Cogan syndrome (0)
Giant cell arteritis (0)
Wegener granulomatosis (0)

New and Updated (in the latest issue of the CLib):